公开(公告)号：US10688186B2

公开(公告)日：2020-06-23

申请号：US15690192

申请日：2017-08-29

申请人： Tiziana Life Sciences PLC

发明人： Kunwar Shailubhai

IPC分类号： A61K39/395 ,  A61K47/20 ,  C07K16/28 ,  A61P1/16 ,  A61P37/06 ,  A61K9/48 ,  A61K45/06 ,  A61K47/02 ,  A61K47/12 ,  A61K47/18 ,  A61K47/26 ,  A61K39/00

摘要： This invention relates to therapeutic, diagnostic and/or prophylactic formulations and dosages and dosing regimens of anti-CD3 antibodies, as well as to methods for using such formulations and dosages and dosing regimens.

公开(公告)号：US11975111B2

公开(公告)日：2024-05-07

申请号：US17193058

申请日：2021-03-05

申请人： Tiziana Life Sciences PLC

发明人： Kunwar Shailubhai

IPC分类号： A61K9/51 ,  A61K9/00 ,  A61K31/7068 ,  A61K38/12 ,  A61K45/06 ,  A61K47/24

CPC分类号： A61K9/5153 ,  A61K9/0019 ,  A61K31/7068 ,  A61K38/12 ,  A61K45/06 ,  A61K47/24 ,  A61K31/7068 ,  A61K2300/00

摘要： The disclosure provides compositions comprising dactinomycin, formulated for delivery by nanoparticle, and methods for treating a myelodysplastic syndrome (MDS) or cancer, for example, NPM1-mutated acute myeloid leukemia (AML), by administration of the compositions of the disclosure.

公开(公告)号：US10973773B2

公开(公告)日：2021-04-13

申请号：US15703953

申请日：2017-09-13

申请人： Tiziana Life Sciences PLC

发明人： Kunwar Shailubhai

IPC分类号： A61K9/51 ,  A61K38/12 ,  A61K45/06 ,  A61K31/7068 ,  A61K47/24 ,  A61K9/00

摘要： The disclosure provides compositions comprising dactinomycin, formulated for delivery by nanoparticle, and methods for treating a myelodysplastic syndrome (MDS) or cancer, for example, NPM1-mutated acute myeloid leukemia (AML), by administration of the compositions of the disclosure.

公开(公告)号：US10758541B2

公开(公告)日：2020-09-01

申请号：US16182036

申请日：2018-11-06

申请人： Tiziana Life Sciences PLC

发明人： Kunwar Shailubhai

IPC分类号： A61K31/519 ,  A61K31/4412 ,  A61K31/47 ,  A61K9/00 ,  A61P35/00 ,  A61K31/404 ,  A61K9/20 ,  A61K9/48

摘要： This application relates to methods of treating and/or preventing cancer (e.g., non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, thyroid carcinoma, colorectal cancer, gastrointestinal stromal tumors, breast cancer, prostate cancer, pancreatic cancer, or thymoma) in patients in need thereof comprising administering to the patient a therapeutically effective amount of a CDK inhibitor (e.g., milciclib) in combination with a therapeutically effective amount of another anticancer drug (e.g., sorafenib, lenvatinib, regorafenib, sunitinib, nivolumab, gemcitabine, and palbociclib).